LSTA

Lisata Therapeutics Inc

1.04

Oct 20 • 3:59 PM ET +0.04 (4.00%)

1.04

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: RNXT PPCB SLXN ELTX ONCY PMCB FTH TPST PCSA IMNN

| Held by: VTI VXF DFSU DCOR

Scroll to Statements

Index	-
Market Cap	9.37M
Enterprise Value	-1.32M
Income	-14.62M
Sales	0.10M
Book/sh	0.90
Cash/sh	1.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Nov 03, 1995

P/E	-
Forward P/E	-
PEG	-
P/S	93.70
P/B	1.15
P/C	0.90
P/FCF	-
EV/EBITDA	-
EV/Sales	-13.20
Quick Ratio	3.69
Current Ratio	3.69
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.64
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	43.29% 24.76%
Sales past 3/5Y	- -
EPS Y/Y TTM	26.48%
Sales Y/Y TTM	-90.65%
EPS Q/Q	40.58%
Sales Q/Q	-100.00%
Earnings	-
EPS/Sales Surpr.	-45.10% -

Insider Own	24.00%
Insider Trans	0.00%
Inst Own	13.54%
Inst Trans	-4.99%
ROA	-80.81%
ROE	-99.89%
ROIC	-177.35%
Gross Margin	36.00%
Oper. Margin	-16427.00%
Profit Margin	-14621.00%
SMA20	-17.05%
SMA50	-26.27%
SMA200	-65.70%
Trades

Shs Outstand	9.12M
Shs Float	6.80M
Short Float	0.58%
Short Ratio	0.13
Short Interest	0.04M
52W High	5.07 -79.49%
52W Low	0.96 8.29%
Volatility	7.21% 9.45%
ATR (14)	0.14
RSI (14)	35.54
Beta	1.01
Rel Volume	0.37
Avg Volume	303.33K
Volume	113,744

Perf Week	-3.70%
Perf Month	-33.33%
Perf Quarter	-52.73%
Perf Half Y	-67.30%
Perf YTD	-44.09%
Perf Year	-57.55%
Perf 3Y	-51.40%
Perf 5Y	-94.07%
Perf 10Y	-98.36%
Recom	1.00
Target Price	4.00
Prev Close	1.00
Price	1.04
Change %	4.00%

Oct-15-26 08:41AM	Lisata adds biopharma finance veteran Jeffrey Farrow to board (Proactive)
Oct-14-26 04:05PM	Lisata Therapeutics Appoints Jeff Farrow to Board of Directors (GlobeNewswire) -5.56%
Oct-08-26 09:10AM	Lisata Therapeutics wins new US patent for pancreatic cancer drug (Proactive)
08:00AM	Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors (GlobeNewswire)
Oct-05-26 09:43AM	Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial (Proactive) -14.29%
08:00AM	Loading…
08:00AM	Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly (GlobeNewswire)
07:03AM	MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher (Proactive)
Sep-24-26 08:55AM	Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions (Proactive)
08:00AM	Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 (GlobeNewswire)
07:15AM	MARKETS LIVE: Wall Street ends mixed as Hormuz hopes ease Middle East jitters (Proactive)
Sep-17-26 05:39PM	Lisata deal propels Mareas drug pipeline to Wall Street (BioPharma Dive) +18.37%
10:15AM	Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement (Proactive)
09:26AM	Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement (GlobeNewswire)
Aug-04-26 08:48AM	Lisata Therapeutics moves forward with legal action following Kuva merger termination (Proactive) +9.62%
07:00AM	Lisata Therapeutics Provides Update Following Termination of Merger Agreement (GlobeNewswire)
09:00AM	Loading…
Jun-16-26 09:00AM	Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-10-26 09:36AM	Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share (Proactive)
08:44AM	Dow Jones, Nasdaq lower after CPI inflation print raises Fed worries (Proactive)
08:00AM	Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. (GlobeNewswire)
May-14-26 05:22PM	Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? (PR Newswire) -6.10%
Mar-09-26 03:43PM	Nasdaq stays green as Middle East war sends oil above $103 (Proactive) +20.57%
10:29AM	Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances (Proactive)
08:29AM	Lisata Therapeutics to be acquired by Kuva Labs (Proactive)
Mar-06-26 06:15PM	Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. (GlobeNewswire)
Feb-11-26 08:02PM	Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jan-28-26 06:41PM	Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-27-26 08:00AM	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide (GlobeNewswire) +12.29%
Jan-21-26 10:31AM	Why Is Lisata Therapeutics Stock Gaining Today? (Benzinga) +86.57%
07:00AM	Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer (GlobeNewswire)
Nov-07-25 12:00AM	Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... (GuruFocus.com) -12.34%
04:05PM	Loading…
Nov-06-25 04:05PM	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' (GlobeNewswire)
Nov-04-25 04:00PM	Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent (GlobeNewswire) -7.49% -5.26%
Oct-30-25 08:00AM	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 (GlobeNewswire)
Oct-13-25 08:00AM	Lisata Therapeutics to Present at LD Micro Main Event XIX (Newsfile)
Oct-09-25 11:16AM	Lisata Therapeutics Partners with Catalent on ADC Technology (Exec Edge)
Oct-08-25 08:30AM	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement (GlobeNewswire)
Sep-30-25 03:04PM	Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer Study (Exec Edge)
Sep-29-25 08:00AM	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial (GlobeNewswire)
Sep-02-25 08:00AM	Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 05:33PM	LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets Investments (Business Wire) -5.41% -7.14%
04:05PM	Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00AM	Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 (GlobeNewswire)
Jul-17-25 02:58PM	Lisata Secures New Composition of Matter Patent for Certepetide (Exec Edge) -6.23%
08:00AM	Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update (GlobeNewswire)
Jul-15-25 08:00AM	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide (GlobeNewswire)
Jun-26-25 08:00AM	Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer (GlobeNewswire) +16.67%
Jun-18-25 05:38AM	Lisata collaborates with GATC Health on drug development (Pharmaceutical Technology)
Jun-17-25 08:00AM	Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development (GlobeNewswire)
Jun-11-25 08:30AM	Lisata Therapeutics to Present at the 2025 BIO International Convention (GlobeNewswire)
May-09-25 03:37AM	Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... (GuruFocus.com) -11.58%
May-08-25 04:05PM	Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 12:40PM	Lisata Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 08:00AM	Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 (GlobeNewswire)
Apr-15-25 08:00AM	Lisata Therapeutics Announces Research License with Catalent (GlobeNewswire) +10.71%
Mar-06-25 08:30AM	Lisata Therapeutics to Present at the Investival Showcase USA (GlobeNewswire)
Mar-05-25 08:30AM	Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development (GlobeNewswire) +10.23%
Feb-28-25 02:35AM	Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... (GuruFocus.com)
Feb-27-25 04:05PM	Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-25 08:00AM	Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025 (GlobeNewswire)
Feb-05-25 08:30AM	Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-25 08:00AM	Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -11.64%
Jan-22-25 08:00AM	Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -29.49%
Jan-15-25 08:30AM	Lisata Therapeutics to Present at the 2025 Sequire Investor Summit (GlobeNewswire)
Dec-11-24 10:52AM	Lisata completes subject enrolment in multi-cancer trial of certepetide (Clinical Trials Arena) -6.93%
10:28AM	Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial (Exec Edge)
Dec-10-24 08:30AM	Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial (GlobeNewswire) +6.63%
Dec-04-24 06:28AM	Lisata and Kuva Labs partner for MR imaging agents to detect cancer (Medical Device Network)
Dec-03-24 08:30AM	Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging (GlobeNewswire)
Nov-19-24 08:30AM	Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year' (GlobeNewswire)
Nov-13-24 08:44AM	Q3 2024 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... (GuruFocus.com)
Nov-12-24 04:05PM	Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 09:23AM	Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration (GlobeNewswire)
08:30AM	Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Nov-01-24 12:00PM	Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know (Zacks) +11.66%
Oct-31-24 08:30AM	Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events (GlobeNewswire)
Oct-28-24 08:30AM	Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis (GlobeNewswire)
Oct-03-24 08:00AM	Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events (GlobeNewswire)
Sep-17-24 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial (GlobeNewswire) +6.53%
Sep-09-24 08:00AM	Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events (GlobeNewswire)
Sep-05-24 08:00AM	Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma (GlobeNewswire) +9.00%
Aug-12-24 04:05PM	Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 08:00AM	Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 (GlobeNewswire) -8.72%
Jul-19-24 06:32AM	Lisata to use Haystacks MRD tests for pancreatic cancer therapy trial (Medical Device Network)
Jul-18-24 11:13AM	Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy (Exec Edge)
08:00AM	Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD Technology to Evaluate Efficacy of Pancreatic Cancer Therapy (GlobeNewswire)
07:30AM	EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy (Benzinga)
Jul-16-24 10:22AM	Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why (Zacks)
08:00AM	Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma (GlobeNewswire)
Jul-10-24 08:00AM	Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model (GlobeNewswire)
Jun-14-24 09:20AM	Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial (Exec Edge)
09:19AM	Lisata Therapeutics CEO encouraged by progress on pancreatic cancer trial (News Direct)
Jun-13-24 08:30AM	Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial (GlobeNewswire)
May-28-24 08:30AM	Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events (GlobeNewswire)
May-20-24 03:58PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
11:14AM	Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment (MT Newswires)
08:30AM	Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer (GlobeNewswire)
May-13-24 10:45AM	Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results (News Direct) -5.93%
May-10-24 12:39PM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript (Insider Monkey)

Show Previous News

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

B.Sc. (Hons.)Dr. David J. Mazzo B.A. (Hons)

SVP of Finance and Treasury & Chief Accounting OfficerMr. James Nisco

M.D.Dr. Joshua Lehrer-Graiwer FACC

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LSTA

Lisata Therapeutics Inc

Upgrade your Finviz experience